poly ADP-ribose polymerase (PARP) inhibitor

systematic review meta-analysis network meta-analysis

Select advanced breast cancer (metastatic)ovarian cancer All type of patientBRCA-mutatedHER 2 negative patientspatients with BRCA mutationpatients without BRCA mutation       PARP inhibitorspoly ADP-ribose polymerase (PARP) inhibitor rucaparibniraparib olaparibtalazoparib veliparib vs placebo       BRCA-mutatedHER-2 negative

Filter

Group by Group by... nothing pathology treatment patient comparator classe classe comparator mechanism clinical condition MA  in first nothing pathology treatment patient comparator classe classe comparator mechanism clinical condition  in second nothing pathology treatment patient comparator classe classe comparator mechanism clinical condition  in third	Description Synopsis Comparison Treatments Patients Characteristics Method Risk of bias References None Tools Indexation					Results Global trial result Main results All results All result tag NCT results	progression or death (progression free survival PFS) (10)death (overall survival) (4) Options Numeric bar chart forest plot medians
Trial	Studied trt	Control trt	patients	tags	ROB	Trial result	progression or death (progression free survival PFS)	death (overall survival)
advanced breast cancer (metastatic)
olaparib
OlympiAD, 2017      NCT	olaparib	Physician s choice chemotherapy		BRCA-mutated HER-2 negative	Risk of bias	conclusive
ovarian cancer
niraparib
ENGOT-OV16/NOVA non-gBRCA      NCT	niraparib	placebo			Low risk of bias	suggesting
ENGOT-OV16/NOVA gBRCA, 2017      NCT	niraparib	placebo		BRCA-mutated	Low risk of bias	suggesting
olaparib
SOLO2/ENGOT-Ov21      NCT	olaparib	placebo		BRCA-mutated	Low risk of bias	suggesting
Ledermann, 2012      NCT	olaparid	placebo			Exploratory	suggesting